Multiple Defects in Muscle Glycogen Synthase Activity Contribute to Reduced Glycogen Synthesis in Non-Insulin Dependent Diabetes Mellitus

Anne W. Thorburn, Barry Gumbiner, Fred Bulcak, Ginger Brechtel, and Robert R. Henry
Department of Medicine, University of California, San Diego; and the Metabolism Division, Veterans Administration Medical Center, San Diego, California 92161

Abstract

To define the mechanisms of impaired muscle glycogen synthase and reduced glycogen formation in non-insulin dependent diabetes mellitus (NIDDM), glycogen synthase activity was kinetically analyzed during the basal state and three glucose clamp studies (insulin ≈ 300, 700, and 33,400 pmol/liter) in eight matched nonobese NIDDM and eight control subjects. Muscle glycogen content was measured in the basal state and following clamps at insulin levels of 33,400 pmol/liter. NIDDM subjects had glucose uptake matched to controls in each clamp by raising serum glucose to 15–20 mmol/liter.

The insulin concentration required to half-maximally activate glycogen synthase (ED₅₀) was approximately fourfold greater for NIDDM than control subjects (1,004±264 vs. 257±110 pmol/liter, P < 0.02) but the maximal insulin effect was similar. Total glycogen synthase activity was reduced ~ 38% and glycogen content was ~ 30% lower in NIDDM. A positive correlation was present between glycogen content and glycogen synthase activity (r = 0.51, P < 0.01).

In summary, defects in muscle glycogen synthase activity and reduced glycogen content are present in NIDDM. NIDDM subjects also have less total glycogen synthase activity consistent with reduced functional mass of the enzyme. These findings and the correlation between glycogen synthase activity and glycogen content support the theory that multiple defects in glycogen synthase activity combine to cause reduced glycogen formation in NIDDM. (J. Clin. Invest. 1991. 87:489–495.)

Key words: insulin action • glucose disposal • nonoxidative glucose metabolism • enzyme kinetics • glucose-6-phosphate

Introduction

Glycogen synthesis is a major pathway of glucose disposal in skeletal muscle (1). Changes in the activity of glycogen synthase (EC 2.4.1.11), either by allosteric regulators or covalent modification, regulate the synthesis of glycogen. In muscle, glycogen synthase exists mainly in active dephosphorylated forms or less active phosphorylated forms (2). These forms are interconverted by protein kinase and phosphatase reactions with glucose-6-phosphate (G6P) stimulating the phosphatase react-

Address reprint requests to Dr. Robert R. Henry, Veterans Administration Medical Center (V-111G), 3350 La Jolla Village Drive, San Diego, CA 92161.

Received for publication 27 April 1990 and in revised form 27 September 1990.

1. Abbreviations used in this paper: FFM, fat-free mass; G6P, glucose-6-phosphate; NIDDM, non-insulin dependent diabetes mellitus; UDGP, uridine 5'-diphosphate glucose.

The Journal of Clinical Investigation, Inc.
Volume 87, February 1991, 489–495
diabetes mellitus and nondiabetic (control) subjects over a range of insulin concentrations from basal to 33,400 pmol/liter. To examine any defects at each insulin level independent of reduced glucose uptake, studies were performed at equivalent rates of glucose uptake in the NIDDM and control subjects.

**Methods**

**Subjects.** Eight male subjects with NIDDM and eight male nondiabetic (control) subjects with normal glucose tolerance (18) were studied. Table I lists the clinical characteristics of the subjects. Age, weight, fat-free mass (FFM), and body mass index were not significantly different in the NIDDM and control subjects. The NIDDM subjects did not have significant diabetic complications or hypertension. Five subjects were on sulfonylurea therapy, one was on insulin, one was on diet therapy only, and one had been recently diagnosed and not yet treated. All treatment for diabetes was withdrawn at least two weeks before the studies. No subject was taking any other medication known to affect carbohydrate metabolism. Duration of overt diabetes was 10±3 yr (mean±SEM). Fasting glycosylated hemoglobin in the NIDDM subjects was 9±1.2%. The normal reference range for this assay is 4.1-8.1%. The control subjects were screened to ensure they were healthy and had no family history of diabetes. Some of the data derived from these studies has been reported previously (17, 20, 21). Written informed consent was obtained from each subject and the experimental protocol approved by the Committee on Human Investigation of the University of California, San Diego.

**Study protocol.** Subjects were admitted to the Special Diagnostic and Treatment Unit of the Veterans Administration Medical Center in San Diego and consumed a weight-maintenance standardized solid diet containing 55% of calories as carbohydrate, 30% as fat, and 15% as protein during hospitalization.

Three studies were carried out in both the NIDDM and control subjects. Each study was performed after a 12-14 h overnight fast and lasted ~7.5 h: a 2.5-h basal period followed by a 5-h hyperinsulinemic glucose clamp. Basal serum glucose and insulin concentrations were higher in the NIDDM than in control subjects (P < 0.05, Table II). The serum glucose and insulin levels used during the clamps are also listed in Table II. Clamps A, B, and C were conducted at insulin infusion rates of 150, 300, and 4,000 pmol/m² per min, respectively (equivalent to ~20, 40, and 600 mU/m² per min). Clamps A and B were carried out at euglycemia (5 mmol/liter) in the control subjects and at hyperglycemia (15-20 mmol/liter) in the NIDDM subjects to match glucose uptake rates in the NIDDM group to those of the control group. Clamp C was carried out first in the NIDDM subjects at pharmacologic insulin concentrations and hyperglycemia (15-20 mmol/liter) to maximally stimulate glucose uptake. In the control subjects, clamp C was then conducted at the same insulin level as the NIDDM group and glucose uptake rate was matched to the NIDDM subjects by varying the level of hyperglycemia.

Details of the study procedures have been described previously (17, 22). Briefly, 34Hglucose was infused as a 45-µCi bolus dose followed by a continuous infusion of 0.60 µCi/min during the entire study to isotopically determine rates of hepatic glucose output and glucose appearance (23, 24). Glucose uptake rates (in milligrams per kilogram FFM per minute) were calculated during the basal state in each subject from the rate of glucose appearance corrected for changes in glucose pool size and urinary glucose loss, if present. Glucose uptake rates were calculated during each clamp study in each subject from the glucose infusion rate corrected for changes in glucose pool size, urinary glucose loss, and residual HGO. The clamp was started with an intravenous infusion of insulin (crystalline human insulin [Humulin R], kindly supplied by Eli Lilly & Co., Indianapolis, IN) given as a bolus followed by a continuous rate of insulin infusion. Serum glucose was clamped at the desired concentration by varying the infusion of 20% glucose. Somatostatin (0.08 pmol/kg per min, cyclic form; Bachem Inc., Torrance, CA) was infused in all studies to suppress endogenous insulin secretion. KCl and K3PO4 were infused at a rate of 0.16 mmol/liter to maintain serum potassium levels. During the last 30 min of the basal and clamp periods, steady-state measurements were made of rates of glucose uptake, serum glucose, and serum insulin. Glycogen synthase activity in samples of vastus lateralis muscle was determined four times in each subject; at the end of one of the basal periods and at the completion of each of the three clamp studies. Glycogen content was also measured in muscle collected from basal and clamp C studies to determine whether glycogen synthase correlated with the glycogen content in muscle from the NIDDM and control subjects in these studies. Glycogen was not measured in clamps A and B since the expected increase in glycogen would likely be within the coefficient of variation of the measurement for muscle glycogen from biopsy samples (25).

**Glycogen synthase determination.** Percutaneous muscle biopsies were obtained from the vastus lateralis muscle with a 5-mm diameter side-cutting needle using a modification of the procedure described by Bergstrom (26). Muscle samples were blotted to remove any blood, immediately placed into liquid nitrogen, and stored until assayed. Glycogen synthase (EC 2.4.1.11) was measured using modifications of the methods of Nuttall et al. (27) and Thomas et al. (28). This modified method has been described in detail previously (14, 17, 29). Glycogen synthase activity was assayed in a homogenate of 50 mg of muscle by measuring the incorporation of [3H]glucose from uridine 5'-diphosphate glucose (UDP-glucose) into glycogen. Protein was also assayed in the extract (30) and units of glycogen synthase activity expressed as nanomoles of [14C]UDPG incorporated into glycogen per minute per milligram of protein. Glycogen synthase activity was assayed over a range of glucose-6-phosphate concentrations (0, 0.1, 0.3, 0.5, 1.0, 5.0, and 10.0 mmol/liter G6P) at physiologic levels of substrate (0.3 mmol/liter).

**Table I. Clinical Characteristics of the Subjects***

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>Weight (kg)</th>
<th>Fat-free mass (kg)</th>
<th>Body mass index (kg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIDDM</td>
<td>59±3</td>
<td>78.8±5.0</td>
<td>60.5±3.8</td>
</tr>
<tr>
<td>Control</td>
<td>58±5</td>
<td>74.2±4.0</td>
<td>56±2.7</td>
</tr>
</tbody>
</table>

* Data expressed as mean±SEM.

† Determined by underwater weighing with correlation for residual lung volume (19).

<table>
<thead>
<tr>
<th>Serum glucose</th>
<th>Serum insulin</th>
<th>Glucose uptake</th>
<th>mg/kg FFM per min</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmol/liter</td>
<td>pmol/liter</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIDDM</td>
<td>9.9±1.1*</td>
<td>64±14²</td>
<td>3.75±0.23³</td>
</tr>
<tr>
<td>Control</td>
<td>4.9±0.1</td>
<td>36±7</td>
<td>2.49±0.10</td>
</tr>
<tr>
<td><strong>Clamp A</strong></td>
<td>20.7±1.6ª</td>
<td>258±57</td>
<td>8.62±0.49</td>
</tr>
<tr>
<td><strong>Clamp B</strong></td>
<td>5.1±0.1</td>
<td>287±43</td>
<td>8.25±0.48</td>
</tr>
<tr>
<td><strong>NIDDM</strong></td>
<td>17.6±2.2ª</td>
<td>646±65</td>
<td>11.24±0.34</td>
</tr>
<tr>
<td><strong>Clamp C</strong></td>
<td>5.1±0.1</td>
<td>740±72</td>
<td>11.76±0.75</td>
</tr>
<tr>
<td><strong>NIDDM</strong></td>
<td>18.4±1.2</td>
<td>33136±2369</td>
<td>25.58±1.66</td>
</tr>
<tr>
<td>Control</td>
<td>15.3±2.2</td>
<td>34694±5873</td>
<td>27.2±1.28</td>
</tr>
</tbody>
</table>

4 P < 0.05, 5 P < 0.01, and 6 P < 0.001 for NIDDM vs. control values.
Results

Rates of glucose uptake (Table II)

In the basal state, rates of glucose uptake were 51% higher in the NIDDM than control subjects (Table II, P < 0.001). When insulin levels were raised to ~ 300 pmol/liter in clamp A, performed at euglycemia in the control subjects, the glucose uptake rate increased threefold from basal to 8.25 mg/kg FFM per min. A similar glucose uptake rate was achieved in clamp A in the NIDDM subjects at the same insulin level by increasing the serum glucose concentration to ~ 20 mmol/liter (P < 0.05 vs. controls). In clamp B, glucose uptake was stimulated further to ~ 11.5 mg/kg FFM per min in both subject groups by increasing insulin levels to ~ 700 pmol/liter, and increasing serum glucose to ~ 18 mmol/liter in the NIDDM subjects while maintaining serum glucose at euglycemia in the control subjects. Maximal rates of glucose uptake were achieved in clamp C in the NIDDM subjects by raising insulin levels to ~ 33,000 pmol/liter and increasing serum glucose to ~ 18 mmol/liter. Glucose uptake in clamp C in the control group was matched to the NIDDM subjects using a similar insulin level while increasing serum glucose to ~ 15 mmol/liter.

Insulin dose-response curves for glycolgen synthase activation (Figs. 1 and 2)

Effect of insulin on glycogen synthase activity at physiologic levels of substrate (UDPG = 0.3 mmol/liter) (Fig. 1). Fig. 1 illustrates the insulin dose-response activation of glycogen synthase activity expressed as fractional velocity in the NIDDM and control subjects. In both the NIDDM and control groups, insulin significantly stimulated glycogen synthase activity. However, activation of glycogen synthase by insulin was significantly reduced in the NIDDM compared with control subjects in the basal state and at matched physiologic stimulated rates of glucose uptake (clamps A and B). Glycogen synthase was reduced by 52% at basal (P < 0.01), 46% during clamp A (P < 0.02) and 35% during clamp B (P < 0.04). Glycogen synthase activity was not significantly different, however, during clamp C.

Kinetic analysis of individual dose-response curves revealed a significantly higher insulin concentration for half-maximal stimulation of glycogen synthase activity (ED50) in NIDDM compared with control subjects (1,004±264 vs. 257±110 pmol/liter, respectively, P < 0.02). However, the maximal effect of insulin on glycogen synthase activity (Vmax) was similar in the NIDDM and control subjects (0.230±0.021 vs. 0.206±0.023, respectively, P = NS).

Effect of insulin on total glycogen synthase activity at maximal concentrations of substrate (UDPG = 5 mmol/liter) and

Acknowledgments

This study was supported by grants from the American Heart Association, the Young Alumni Fund of the University of Pennsylvania, the Fulbright Program of the U.S. Government, and National Institutes of Health (DK 11607, HD 17036, HH 23995). We thank Dr. H. Sittinger for supplying the insulins and J. M. McCall for editorial assistance.

Reference

Figure 2. Effect of insulin on total glycogen synthase activity (in nanomoles per minute per milligram protein) at saturating levels of UDPG (5 mmol/liter) and G6P (10 mmol/liter) in NIDDM and control subjects under basal conditions (circles) and three glucose clamps (clamp A, squares, 300 pmol/liter; clamp B, triangles, 700 pmol/liter; clamp C, diamonds, 33,400 pmol/liter). Significant differences between subject groups were found in the basal state ($P < 0.05$) and during clamp C ($P < 0.03$).

activator (G6P = 10 mmol/liter) (Fig. 2). Fig. 2 illustrates the insulin dose-response curves for total glycogen synthase activity (expressed in nanomoles per minute per milligram protein) in the NIDDM and control subjects at maximal concentrations of both substrate (UDPG, 5 mmol/liter) and allosteric activator (G6P, 10 mmol/liter). Within both the NIDDM and control groups, insulin did not significantly increase total glycogen synthase activity. Mean total glycogen synthase activity was ~38% lower under all conditions (basal and stimulated) for the NIDDM compared with control subjects.

Glucose 6-phosphate dose-response curves for glycogen synthase activity at physiologic levels of substrate (UDPG = 0.3 mmol/liter) (Figs. 3 and 4)

The G6P dose-response curves for glycogen synthase activity (in nanomoles per minute per milligram protein) for the NIDDM and control subjects are illustrated in Fig. 3. As the insulin concentration increased there was a leftward shift in the dose-response curves. The shift was less pronounced, however, for NIDDM than control subjects. To analyze these sigmoidal G6P dose-response curves (Fig. 3), kinetic analysis was performed using the Eadie-Hofstee equation (see Methods) to determine the half-maximal activation of glycogen synthase by G6P ($A_0.5$). Fig. 4 illustrates the insulin dose-response curves for the $A_0.5$ for G6P in the NIDDM and control subjects. Insulin decreased the $A_0.5$ for G6P in both the NIDDM and control groups. However, $A_0.5$ values for basal and clamp A were significantly higher for the NIDDM than control subjects (4.49±0.97 vs. 2.86±1.09 for basal, and 1.57±0.23 vs. 0.64±0.08 mmol/liter for clamp A, both $P < 0.01$). As insulin levels increased above ~700 pmol/liter in clamps B and C, no significant differences were observed in $A_0.5$ between the NIDDM and control subjects.

Muscle glycogen content (Table III)

The muscle glycogen content in the basal state and during clamp C in NIDDM and control subjects is shown in Table III. In the NIDDM subjects, glycogen was 33% and 29% lower...
under basal and clamp C conditions, respectively, compared with control subjects, although this reached significance only under basal conditions ($P < 0.02$). Glycogen increased significantly by 67% ($P < 0.005$) and 57% ($P < 0.05$) as insulin levels increased from basal to clamp C for NIDDM and control subjects, respectively. These increments were not significantly different (159.3±37.0 vs. 204.2±84.1 mmol glycosyl units/kg dry muscle in the NIDDM and control subjects, respectively, $P = N S$). As shown in Fig. 5, a significant correlation was found between glycogen content and glycogen synthase activity when individual subjects' data for the basal and clamp C studies were plotted ($r = 0.51$, $P < 0.01$).

**Discussion**

This study has demonstrated that multiple defects in muscle glycogen synthase activity are present in NIDDM and associated with reduced muscle glycogen formation. Although impaired muscle glycogen synthase activity in response to insulin has been well documented in a number of insulin-resistant states (7, 12–17), little is known about the nature or extent of these defects. In a previous study carried out during steady-state glucose clamp conditions and insulin levels of 300 pmol/liter, we documented that muscle glycogen synthase activity (expressed as fractional velocity) was reduced by 40% in NIDDM but could be normalized by increasing insulin levels fourfold (17).

The results of this study led us to examine this defect in greater depth and we have now shown that the fractional velocity of glycogen synthase is reduced by 35–52% at insulin levels ranging from basal to ~700 pmol/liter. As insulin levels increased, the magnitude of the impairment progressively decreased and at pharmacologic insulin levels of ~33,400 pmol/liter the defect normalized. Kinetic analysis of the insulin dose-response curves showed that the half-maximal activation constant for insulin was approximately fourfold higher for NIDDM than control subjects, but with no difference in the maximal effect of insulin on glycogen synthase. One possible explanation for the normalization of maximal glycogen synthase activity in NIDDM may be stimulation of enzyme activity by G6P secondary to glucose transport, originally proposed by Lawrence and Larner (33). Therefore, reduced sensitivity of glycogen synthase to physiologic insulin concentrations exists in NIDDM that is overcome when insulin is raised to pharmacologic levels.

In agreement with previous reports (25, 34), at each insulin concentration glycogen synthase was activated in the control subjects without changing the total glycogen synthase activity (i.e., the true maximal activity at saturating concentrations of G6P and UDPG). Similarly, increasing insulin levels from basal to clamp C did not significantly change total glycogen synthase activity in the NIDDM subjects. Although total activity was less in the NIDDM subjects than in controls over the range of insulin concentrations studied, it was significantly less only in the basal state and during clamp C. Alterations in the turnover rate of glycogen synthase, such as a decrease in the rate of synthesis, increase in the rate of degradation, or some combination of the two could be responsible for reduced total enzyme activity in NIDDM. Alternatively, NIDDM and control subjects may possess identical amounts of glycogen synthase protein but the enzyme simply has less activity in NIDDM. Whatever the cause, our data strongly suggest that NIDDM subjects have a reduced functional mass of the enzyme, which is not overcome by acutely increasing the serum insulin concentration.

Insulin acts as a major regulator of glycogen synthase in muscle by dephosphorylating the enzyme and reducing the $A_{0.5}$ for G6P. G6P is not only an allosteric effector but also a messenger molecule that can mediate hormone action by stimulating the phosphatase reaction (4, 5). In muscle from diabetic rabbits, the half-maximal G6P activation constant for glycogen synthase has been shown to increase by two to threefold compared with nondiabetic animals (11). Our study has now similarly demonstrated that reduced sensitivity of muscle glycogen synthase to allosteric activation by G6P exists in NIDDM. This is an expected finding since the elevated $A_{0.5}$ of glycogen synthase for G6P is likely the result of the increased phosphorylation state of the enzyme, shown by Roach and Larner to be associated with reduced fractional glycogen synthase activity (35). The reduced sensitivity to G6P was overcome at insulin concentrations above 700 pmol/liter since insulin presumably dephosphorylates glycogen synthase to such an extent that the enzyme no longer requires G6P for complete activation.

This study not only examined the extent of defects in glycogen synthase activation by insulin in NIDDM, but also demonstrated that defects in glycogen synthase activity contribute to reduced glycogen content in NIDDM. This study now confirms that glycogen content is reduced in NIDDM, and that glycogen synthase activity remains impaired at physiologic in-
sulin concentrations even when rates of glucose uptake are normalized. Furthermore, a close correlation between glycolgen synthase activity and glucogen content has been clearly demonstrated. Thus, these findings taken together are consistent with the notion that changes in glycolgen synthase activity contribute significantly to decreased glucogen content in NIDDM.

When a defect in insulin’s ability to activate glycolgen synthase has been reported previously, it has usually been accompanied by a corresponding reduced rate of glucose uptake into insulin-sensitive tissues (e.g., 7, 12–16). This association has lead to the suggestion that a causal relationship exists between insulin-stimulation of glycolgen synthase and glucose uptake (7, 13, 14). However, the fact that we found reduced glycolgen synthase activity in NIDDM subjects when rates of glucose uptake were normalized indicates that the effect of insulin on muscle glycolgen synthase is clearly separable from its effect on glucose transport (2, 17, 25, 36, 37) and confirms that reduced glycolgen synthase activity in NIDDM is not solely a consequence of reduced glucose uptake. Furthermore, this study provides evidence that activation of glycolgen synthase and glucose transport by insulin may occur through different mechanisms.

At present we can only speculate as to the cause of the reduced sensitivity of glycolgen synthase to covalent modification and allosteric activation by insulin and G6P in NIDDM. The most likely explanation is that glycolgen synthase in muscle from NIDDM subjects is more phosphorylated, and hence inactivated, due to an impairment in the complex pattern of hormonally regulated multisite phosphorylation which controls the activity of glycolgen synthase. The recent demonstration by Kida and co-workers that glycolgen synthase phospha-
tase is reduced in insulin-resistant subjects supports this concept (7). Although the etiology of impaired glycolgen synthase activity in NIDDM remains to be determined, it has recently been demonstrated that this defect can be reversed, at least partially, in NIDDM subjects by eight weeks of sulfonylurea therapy (38).

In summary, multiple defects in glycolgen synthase activity and reduced glucogen content exist in muscle from nonobese NIDDM subjects over a range of physiologic insulin concentrations and similar rates of glucose uptake. NIDDM is associated with a defect in the sensitivity of muscle glycolgen synthase to insulin that becomes progressively less as insulin concentrations increase. Increasing the insulin concentration does not, however, overcome the defect in total enzyme activity (i.e., functional enzyme mass). These defects in glycolgen syn-
tase activity and the correlation between glycolgen synthase activity and glucogen content support the contention that multiple defects in glycolgen synthase activity contribute to reduced glucogen deposition in NIDDM.

Acknowledgments

We gratefully acknowledge the helpful advice received from Dr. Harvey Kaslow, University of Southern California, Los Angeles, and Dr. Ted Ciaraldi, Veterans Administration Medical Center, San Diego, and the assistance of Penny Wallace, Therese Flynn, Michelle Goldberg, Cleon Tate, the research volunteers, and the nursing staff of the Division of Endocrinology and Metabolism, VA Medical Center, San Diego.

This study was supported in part by the American Diabetes Association (ADA), the Medical Research Service of the Veterans Administration Medical Center, grant DK-38949 from the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, and grant PHS RR-00827 from the General Clinical Research Branch, Division of Research Resources, National Institutes of Health. Barry Gumbiner is the recipient of an ADA California Affiliate Fellowship Grant. Anne Thorburn is a Neil Hamilton Fairley Fellow funded by the National Health and Medical Research Council of Australia.

References


18. National Diabetes Data Group. 1979. Classification and diagnosis of dia-

cil, National Academy of Sciences, Washington, DC. 78–89.
